A high frequency of CREBBP mutations has also been demonstrated in biopsies from newly-diagnosed DLBCL/HGBL patients undergoing large-scale mutation analysis from the SAAK 38/07 prospective clinical trial cohort [7] as well as those treated in the GOYA study [8], although the predictive value of CREBBP mutations for DFS in GCB DLBCL/HGBL patients was not clearly stated in either analysis. The gene discussed is CREBBP; the disease is diffuse large B-cell lymphoma.